Slamon DJ, Fasching P, Hurvitz S (2023)
Publication Type: Journal article, Erratum
Publication year: 2023
Book Volume: 15
DOI: 10.1177/17588359231201818
[This corrects the article DOI: 10.1177/17588359231178125.].
APA:
Slamon, D.J., Fasching, P., & Hurvitz, S. (2023). Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Therapeutic Advances in Medical Oncology, 15. https://doi.org/10.1177/17588359231201818
MLA:
Slamon, Dennis J., Peter Fasching, and Sara Hurvitz. "Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer." Therapeutic Advances in Medical Oncology 15 (2023).
BibTeX: Download